Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years’ follow-up

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers

(2012) O. Brouckaert et al.   ANNALS OF ONCOLOGY

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement

(2012) S. Guiu et al.   ANNALS OF ONCOLOGY

Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study

(2012) Anna-Karin Falck et al.   BMC CANCER

The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications

(2012) Jonathan P. Sleeman et al.   CLINICAL & EXPERIMENTAL METASTASIS

Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression

(2012) Linda Sofie Lindström et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer

(2012) Aleksandra Markiewicz et al.   Journal of Translational Medicine

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies

(2011) Quinci Romero et al.   BMC CANCER

HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis

(2011) Nehmat Houssami et al.   BREAST CANCER RESEARCH AND TREATMENT

ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer

(2011) Jeanette Dupont Jensen et al.   BREAST CANCER RESEARCH AND TREATMENT

Do all roads lead to Rome? Routes to metastasis development

(2011) Jonathan P. Sleeman et al.   INTERNATIONAL JOURNAL OF CANCER

Clinical Notice for American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations on ER/PgR and HER2 Testing in Breast Cancer

(2011) M. Elizabeth Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer

(2011) Eitan Amir et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

(2011) M. Dowsett et al.   JNCI-Journal of the National Cancer Institute

Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials

(2011) Wenjin Yin et al.   PLoS One

Concordance between HER-2 and steroid hormone receptor expression between primary breast cancer, sentinel node metastases, and isolated tumor cells

(2010) Leena Strien et al.   PATHOLOGY RESEARCH AND PRACTICE

Does Analysis of Biomarkers in Tumor Cells in Lymph Node Metastases Give Additional Prognostic Information in Primary Breast Cancer?

(2010) Anna-Karin Falck et al.   WORLD JOURNAL OF SURGERY

Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

(2010) Fiona M. Blows et al.   PLOS MEDICINE

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   Journal of Oncology Practice

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

(2009) C. Liedtke et al.   ANNALS OF ONCOLOGY

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

(2009) C. Simmons et al.   ANNALS OF ONCOLOGY

Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis

(2009) Nikolas H. Stoecklein et al.   INTERNATIONAL JOURNAL OF CANCER

Disease-Free Survival According to Degree ofHER2Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

(2009) Maggie C. U. Cheang et al.   JNCI-Journal of the National Cancer Institute

The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer

(2009) Marie Klintman et al.   MODERN PATHOLOGY

The Genomic Heritage of Lymph Node Metastases: Implications for Clinical Management of Patients with Breast Cancer

(2008) Tyson E. Becker et al.   ANNALS OF SURGICAL ONCOLOGY